Immunotherapy

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
Paolo A Ascierto, Dirk Schadendorf

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005082; DOI: 10.1136/jitc-2022-005082
Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
Fabiana Pani, Yoshinori Yasuda, Sylvie T Rousseau, Kevin C Bermea, Solmaz Roshanmehr, Rulin Wang, Srinivasan Yegnasubramanian, Patrizio Caturegli, Luigi Adamo

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005538; DOI: 10.1136/jitc-2022-005538
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries, Lynn Feun, Kim A Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Robert H I Andtbacka

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005224; DOI: 10.1136/jitc-2022-005224
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Olivier Michielin, Aly-Khan Lalani, Caroline Robert, Padmanee Sharma, Solange Peters

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003024; DOI: 10.1136/jitc-2021-003024
Gallic acid induces T-helper-1-like T_reg cells and strengthens immune checkpoint blockade efficacy
Biaolong Deng, Biaolong Yang, Jieqiong Chen, Shuaiwei Wang, Weiqi Zhang, Yixian Guo, Yichao Han, Hecheng Li, Yongjun Dang, Yaqin Yuan, Xueyu Dai, Yuansheng Zang, Yangyang Li, Bin Li

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e004037; DOI: 10.1136/jitc-2021-004037
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005543; DOI: 10.1136/jitc-2022-005543
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch
Annelisa M Cornel, Ester Dunnebach, Damon A Hofman, Sanjukta Das, Satyaki Sengupta, Femke van den Ham, Judith Wienke, Josephine G M Strijker, Denise A M H van den Beemt, Anke H W Essing, Bianca Koopmans, Sem A G Engels, Vania Lo Presti, Celina S Szanto, Rani E George, Jan J Molenaar, Sebastiaan van Heesch, Miranda P Dierselhuis, S Nierkens

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005002; DOI: 10.1136/jitc-2022-005002
Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers
Anaïs Jiménez-Reinoso, Néstor Tirado, Alba Martinez-Moreno, Víctor M Díaz, Marina García-Peydró, Oana Hangiu, Laura Díez-Alonso, Ángela Albitre, Petronila Penela, Maria L Toribio, Pablo Menéndez, Luis Álvarez-Vallina, Diego Sánchez Martínez

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005333; DOI: 10.1136/jitc-2022-005333
In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade
Chenkai Mao, Veronique Beiss, Gregory W Ho, Jennifer Fields, Nicole F Steinmetz, Steven Fiering

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005834; DOI: 10.1136/jitc-2022-005834
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade
Ming Zheng

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005670; DOI: 10.1136/jitc-2022-005670

Main menu

Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy

Pages